Physician profile
Hannah Eckberg
NPI 1417503921
$2,203.91
in general payments reported to CMS, 2019-2025
25 companies · $800 in 2025
The $800 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $309 · 2023: $497 · 2024: $597 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.75 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.80 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.09 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $152.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $138.97 | 2023-2025 | |
| Seqirus USA INC | $137.94 | 2023-2025 | |
| Lilly USA, LLC | $135.33 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $108.66 | 2023-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.78 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $91.08 | 2022-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Glaxosmithkline, LLC. | $83.11 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $62.91 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $54.34 | 2022 | |
| Mayne Pharma Commercial LLC | $52.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.77 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $39.73 | 2023-2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $32.83 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $28.10 | 2025 | Auvelity |
| Pulmonx Corporation | $26.46 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Exact Sciences Corporation | $23.79 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $20.36 | 2022 | |
| Neurocrine Biosciences, INC. | $18.44 | 2025 | |
| Daiichi Sankyo INC. | $18.10 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.97 | 2025 | |
| Amgen INC. | $14.90 | 2024 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Eckberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.